Mortality at maximal · people with early‐ or very early‐stage hepatocellular carcinoma ineligible for surgery
It is very uncertain whether percutaneous alcohol injection changes mortality at maximal compared with radiofrequency ablation (very low certainty).
1 finding from 1 review
Cancer‐related mortality at maximal · people with early‐ or very early‐stage hepatocellular carcinoma ineligible for surgery
Percutaneous alcohol injection may leads to higher cancer‐related mortality at maximal compared with radiofrequency ablation (low certainty).
1 finding from 1 review
Serious adverse events (number of participants) · people with early‐ or very early‐stage hepatocellular carcinoma ineligible for surgery
It is very uncertain whether percutaneous alcohol injection changes serious adverse events (number of participants) compared with radiofrequency ablation (very low certainty).
1 finding from 1 review
Serious adverse events (number of events) · people with early‐ or very early‐stage hepatocellular carcinoma ineligible for surgery
It is very uncertain whether percutaneous alcohol injection changes serious adverse events (number of events) compared with radiofrequency ablation (very low certainty).
1 finding from 1 review
Local progression · 1088 patients with early HCC
1 finding from 1 review
Rate of complications · 1088 patients with early HCC
1 finding from 1 review
Length of hospital stay · 1088 patients with early HCC
1 finding from 1 review
Overall survival · 1088 patients with early HCC
1 finding from 1 review
2‐year survival · 1088 patients with early HCC
1 finding from 1 review
Event‐free survival · 1088 patients with early HCC
1 finding from 1 review
Treatment‐related adverse effects · men with chronic (≥ 12 months) Peyronie's disease (single plaque)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Degree of penile curvature · men with chronic (≥ 12 months) Peyronie's disease (single plaque)
1 finding from 1 review
Treatment discontinuation · men with chronic (≥ 12 months) Peyronie's disease (single plaque)
It is very uncertain whether injectional interferon alpha‐2B changes discontinuation from treatment compared with saline (very low certainty).
1 finding from 1 review
Outcomes ( · men with chronic (≥ 12 months) Peyronie's disease (single plaque)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Patient‐reported ability to have intercourse · men with chronic (≥ 12 months) Peyronie's disease (single plaque)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life · men with chronic (≥ 12 months) Peyronie's disease (single plaque)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events (pain and swelling at injection site and limitation of elbow movement following injection) · lateral elbow pain
Autologous blood or PRP showed no clear difference in adverse events (pain and swelling at injection site and limitation… compared with placebo at 3 months' follow‐up (low certainty).
1 finding from 1 review
Intervention not reported
Minor adverse events** ‒short‐term (> 2 weeks but ≤ 3 months) Minor adverse events provided as the proportion of patients reporting any untoward medical occurrence after an epidural injection without hospitalisations. · lumbosacral radicular pain
It is very uncertain whether the intervention changes minor adverse events** ‒short‐term (> 2 weeks but ≤ 3 months) Minor… (very low certainty).
1 finding from 1 review
Intervention not reported
Major adverse events** ‒short‐term (> 2 weeks but ≤ 3 months) Major adverse events provided as the proportion of patients reporting any untoward medical occurrence after an epidural injection with hospitalizations. · lumbosacral radicular pain
1 finding from 1 review
Adverse effects: pain on injection (solution deposition), Heft-Parker VAS 0-170 mm · adults and children undergoing general anaesthesia including the muscle relaxant rocuronium bromide
Adverse effects of pharmacological intervention showed no clear difference in pain on injection compared with control (low certainty).
1 finding from 1 review